Display options
Cite
Spirina LV, Yunusova NV, Kondakova IV, et al. Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception. Heliyon. 2019;5(8):e02090doi: 10.1016/j.heliyon.2019.e02090.
Spirina, L. V., Yunusova, N. V., Kondakova, I. V., & Tarasenko, N. V. (2019). Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception. Heliyon, 5(8), e02090. https://doi.org/10.1016/j.heliyon.2019.e02090
Spirina, Liudmila V, et al. "Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception." Heliyon vol. 5,8 (2019): e02090. doi: https://doi.org/10.1016/j.heliyon.2019.e02090
Spirina LV, Yunusova NV, Kondakova IV, Tarasenko NV. Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception. Heliyon. 2019 Aug 16;5(8):e02090. doi: 10.1016/j.heliyon.2019.e02090. eCollection 2019 Aug. PMID: 31463379; PMCID: PMC6708992.
Copy Download .nbib Format: NLM
Share it on

Heliyon. 2019 Aug 16;5(8):e02090. doi: 10.1016/j.heliyon.2019.e02090. eCollection 2019 Aug.

Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception.

Heliyon

Liudmila V Spirina, Natalia V Yunusova, Irina V Kondakova, Natalia V Tarasenko

Affiliations

  1. Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny Street, Tomsk, 634050, Russia.
  2. Division of Biochemistry and Molecular Biology, Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634050, Russia.
  3. Division of Medical Genetics, Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634050, Russia.
  4. Laboratory of Population Genetics, Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny Street, Tomsk, 634050, Russia.

PMID: 31463379 PMCID: PMC6708992 DOI: 10.1016/j.heliyon.2019.e02090

Abstract

Sex hormones, regulating normal physiological processes of most tissues and organs, are considered to be one of the key factors in the development of hormone-dependent cancer and formation of the hormone-resistant tumor phenotype. Recently, the importance of the system for control of hormone receptors expression mediated by nuclear peptides became evident. This system is involved in the regulation of normal physiological processes, in the pathogenesis of many diseases as well as oncogenesis. In the review, we discuss the relationships of the two regulatory peptides - Brn-3α, TRIM16 with hormone receptors. The transcription factor Brn-3α is able to affect the transcription activity of androgen and estrogen receptors. It is observed the participation of TRIM16 protein in the pathogenesis of hormone-dependent tumors due to its "anti-estrogenic effect". Additionally, they are involved in the key intracellular processes, such as proliferation, cell differentiation, and programmed death - apoptosis. Thus, Brn-3α and TRIM16 are associated with cancer development and progression. By understanding these alterations, we can identify potential markers and novel biochemical therapeutic targets. It makes clear the association between classical hormone-dependent tumors and less sensitive ones with the modification in the level of hormone receptors.

Keywords: Brn-3α; Cancer research; Cancers; Steroid receptors; TRIM16

References

  1. J Biol Chem. 1999 Oct 1;274(40):28521-7 - PubMed
  2. Int J Biochem Cell Biol. 2001 Oct;33(10):1027-39 - PubMed
  3. Oncogene. 2001 Aug 9;20(35):4899-903 - PubMed
  4. Nucleic Acids Res. 2001 Nov 15;29(22):4530-40 - PubMed
  5. Oncogene. 2002 Sep 5;21(39):6123-31 - PubMed
  6. Mol Biotechnol. 2002 Oct;22(2):123-7 - PubMed
  7. Cancer Biol Ther. 2002 Jul-Aug;1(4):428-32 - PubMed
  8. Nucleic Acids Res. 2002 Nov 15;30(22):4872-80 - PubMed
  9. J Biol Chem. 2005 Mar 25;280(12):11851-8 - PubMed
  10. Oncogene. 2006 Jan 5;25(1):51-60 - PubMed
  11. Prostate Cancer Prostatic Dis. 2006;9(1):83-91 - PubMed
  12. J Biol Chem. 2006 Jun 30;281(26):18246-56 - PubMed
  13. Cell. 2006 Nov 3;127(3):469-80 - PubMed
  14. Nat Rev Immunol. 2008 Nov;8(11):849-60 - PubMed
  15. Cancer Lett. 2009 May 8;277(1):82-90 - PubMed
  16. J Biol Chem. 2010 May 14;285(20):15286-95 - PubMed
  17. J Ovarian Res. 2010 Jul 29;3:17 - PubMed
  18. Oncogene. 2010 Nov 18;29(46):6172-83 - PubMed
  19. Bull Exp Biol Med. 2010 Jul;149(1):82-5 - PubMed
  20. Biochim Biophys Acta. 2011 Nov;1813(11):1938-45 - PubMed
  21. J Pathol. 2012 Feb;226(3):451-62 - PubMed
  22. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Jul;27(7):801-2 - PubMed
  23. PLoS One. 2012;7(5):e37470 - PubMed
  24. Apoptosis. 2013 May;18(5):639-51 - PubMed
  25. EMBO Mol Med. 2013 Jun;5(6):919-34 - PubMed
  26. Carcinogenesis. 2014 Sep;35(9):2142-53 - PubMed
  27. Folia Biol (Praha). 2014;60(3):144-51 - PubMed
  28. Oncotarget. 2014 Oct 30;5(20):10127-39 - PubMed
  29. Mol Biol (Mosk). 2014 May-Jun;48(3):444-51 - PubMed
  30. Biochem Biophys Res Commun. 2015 May 15;460(4):1021-8 - PubMed
  31. PLoS One. 2015 Jun 09;10(6):e0128705 - PubMed
  32. Trends Endocrinol Metab. 2015 Sep;26(9):477-85 - PubMed
  33. Oncol Rep. 2016 Feb;35(2):1204-12 - PubMed
  34. Int J Oncol. 2016 Apr;48(4):1639-49 - PubMed
  35. Cancer Lett. 2016 May 1;374(2):315-23 - PubMed
  36. Oncotarget. 2016 Aug 9;7(32):52166-52178 - PubMed
  37. J Biol Chem. 2016 Jul 22;291(30):15909 - PubMed
  38. Dev Cell. 2016 Oct 10;39(1):13-27 - PubMed
  39. Oncol Res. 2017 Apr 14;25(4):551-558 - PubMed
  40. Int J Mol Med. 2016 Dec;38(6):1734-1742 - PubMed
  41. J Clin Endocrinol Metab. 1997 Jan;82(1):89-94 - PubMed
  42. Mol Cell Biol. 1998 Feb;18(2):1029-41 - PubMed
  43. Dev Biol. 1998 May 15;197(2):155-69 - PubMed
  44. Int J Biochem Cell Biol. 1998 Nov;30(11):1153-7 - PubMed

Publication Types